The Petri Dish: Embattled Sesen Bio shuts down via merger


Khosla Ventures is throwing its weight behind a new CRISPR/Cas13 startup, and Sesen Bio, formerly Eleven Biotherapeutics, is finally shutting down after 14 years.

Previous Limit lab construction in the world's biotech capital? A Cambridge proposal could do just that.
Next Angier accelerates growth with more new homes approved

No Comment

Leave a reply

Your email address will not be published.